Evidence map›Paper›PMID 37215150›Full record

ArticleMolecular therapy. Nucleic acids2023

A conditional RNA Pol II mono-promoter drives HIV-inducible, CRISPR-mediated cyclin T1 suppression and HIV inhibition.

Srinivasan Chinnapaiyan, Maria-Jose Santiago, Kingshuk Panda, Md Sohanur Rahman, Jessica Alluin, John Rossi, Hoshang J Unwalla

Open access · goldAbstract read
In one paragraph

Article in Molecular therapy. Nucleic acids, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
0.6field-weighted citation impact, top 31% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 4 citations in OpenAlex.

  1. Review
  2. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 2 institutions in 1 country.

Srinivasan ChinnapaiyanDepartment of Immunology and Nanomedicine, Institute of Neuroimmune Pharmacology, Herbert Wertheim College of Medicine, Florida International University, Miami, FL 33199, USA.
Maria-Jose SantiagoDepartment of Immunology and Nanomedicine, Institute of Neuroimmune Pharmacology, Herbert Wertheim College of Medicine, Florida International University, Miami, FL 33199, USA.
Kingshuk PandaDepartment of Immunology and Nanomedicine, Institute of Neuroimmune Pharmacology, Herbert Wertheim College of Medicine, Florida International University, Miami, FL 33199, USA.
Md Sohanur RahmanDepartment of Immunology and Nanomedicine, Institute of Neuroimmune Pharmacology, Herbert Wertheim College of Medicine, Florida International University, Miami, FL 33199, USA.
Jessica AlluinBeckman Research Institute of the City of Hope National Medical Center, Monrovia Biomedical Research Center MBRC, 1218 S. Fifth Av., Monrovia, CA 91008, USA.
John RossiBeckman Research Institute of the City of Hope National Medical Center, Monrovia Biomedical Research Center MBRC, 1218 S. Fifth Av., Monrovia, CA 91008, USA.
Hoshang J UnwallaDepartment of Immunology and Nanomedicine, Institute of Neuroimmune Pharmacology, Herbert Wertheim College of Medicine, Florida International University, Miami, FL 33199, USA.
Florida International University · USCity Of Hope National Medical Center · US

Funding

Mechanisms of Defective Mitophagy and cellular Senescence in HIV-associated COPDR01HL147715 · NHLBI · FLORIDA INTERNATIONAL UNIVERSITY · PI IRFAN RAHMAN, HOSHANG JEHANGIR UNWALLA · 2019 to 2026
$2.6M
Aberrant Micro-managing of the Airway Epithelial Transcriptome in HIV-associated COPDR01HL167655 · NHLBI · FLORIDA INTERNATIONAL UNIVERSITY · PI IRFAN RAHMAN, HOSHANG JEHANGIR UNWALLA · 2023 to 2026
$2.6M
Resetting the Clock in HIV associated COPDR01HL158316 · NHLBI · FLORIDA INTERNATIONAL UNIVERSITY · PI RAHMAN, IRFAN, UNWALLA, HOSHANG JEHANGIR · 2022 to 2025
$2.1M
Transdisciplinary Training in Biomolecular and Biomedical SciencesT32GM132054 · NIGMS · FLORIDA INTERNATIONAL UNIVERSITY · PI DEGENNARO, MATTHEW, TSE-DINH, YUK-CHING · 2019 to 2023
$1.6M
NHLBI NIH HHS R01 HL147715NHLBI NIH HHS R01 HL158316NHLBI NIH HHS R01 HL167655NIGMS NIH HHS T32 GM132054
6 · The paper itself

Abstract

Gene editing using clustered regularly interspaced short palindromic repeats (CRISPR) targeted to HIV proviral DNA has shown excision of HIV from infected cells. However, CRISPR-based HIV excision is vulnerable to viral escape. Targeting cellular co-factors provides an attractive yet risky alternative to render viral escape irrelevant. Cyclin T1 is a critical modulator of HIV transcription and mediates recruitment of positive transcription elongation factor-b (P-TEFb) kinase for transcriptional elongation. Hence, a CRISPR-mediated cyclin T1 inactivation will silence HIV transcription, locking it in an inactive form in the cell and thereby serving as an effective antiviral and possibly effecting a functional cure. However, cellular genes play important roles, and their uncontrolled inhibition can promote undesirable effects. Here, we demonstrate a conditional inducible RNA polymerase II (RNA Pol II) mono-promoter-based co-expression of a CRISPR system targeting cyclin T1 from a single transcription unit. Co-expression of guide RNA (gRNA) and CRISPR-associated protein (Cas9) is observed only in HIV-infected cells and leads to sustained HIV suppression in stringent chronically infected cell lines as well as in T cell lines. We further show that incorporation of

Indexed as

CRISPR-Cas9cyclin T1gene therapyHIV inducible fusion promoterHIV latencyHIV reservoirsHIV silencingminizymesMT: RNA/DNA EditingRNA polymerase II

Identifiers

PMID37215150
PMCPMC10192333
OpenAlexW4366438789

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.